Roche Diagnostics Named to FORTUNE magazine's 2013 list of "100 Best Companies to Work For"

Roche Diagnostics Named to FORTUNE magazine's 2013 list of "100 Best Companies
                                 to Work For"

Roche Diagnostics joins Google, Starbucks and Nordstrom on list

PR Newswire

INDIANAPOLIS, Jan. 17, 2013

INDIANAPOLIS, Jan. 17, 2013 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY)
announced today that Roche Diagnostics Corporation has been selected to
FORTUNE magazine's annual list of the "100 Best Companies to Work For." Roche
debuted at 89 on the list and is the only Indiana-based company selected.

(Photo: )

"Being named a 'Best Company to Work For' validates what we already know about
our organization," said Jack Phillips, president and CEO of Roche Diagnostics.
"Roche is not only a leader in personalized healthcare; we're also a leader in
attracting and developing the best people. We are successful only because our
people are successful and I couldn't be prouder that our entire workforce is
being recognized by this award."

In selecting Roche Diagnostics for the list, Fortune magazine cited the
company's on-site medical clinic and fitness center; $30,000 budget for
intramural sports; and health insurance plans tiered to income levels.

The entire list of the 2013 "100 Best Companies to Work For" is available at

About Roche

Headquartered in Basel, Switzerland, Roche is a leader in research-focused
healthcare with combined strengths in pharmaceuticals and diagnostics. Roche
is the world's largest biotech company with truly differentiated medicines in
oncology, virology, inflammation, metabolism and CNS. Roche is also the world
leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer
in diabetes management. Roche's personalized healthcare strategy aims at
providing medicines and diagnostic tools that enable tangible improvements in
the health, quality of life and survival of patients. In 2011, Roche had over
80,000 employees worldwide and invested over 8 billion Swiss francs in R&D.
The Group posted sales of 42.5 billion Swiss francs. Genentech, United States,
is a wholly owned member of the Roche Group. Roche has a majority stake in
Chugai Pharmaceutical, Japan. For more information: or

All trademarks used or mentioned in this release are protected by law.

For further information, please contact:

Todd Siesky
Director, Corporate Communications
Roche Diagnostics Corporation
Indianapolis, IN
(317) 521-3966

SOURCE Roche Diagnostics

Press spacebar to pause and continue. Press esc to stop.